Immunotherapy works by enhancing the immune system rather than directly attacking cancer cells. RGA’s clinical oncologist, Dr. Radi Counsell, discusses how modern approaches to immunotherapy are transforming cancer survival rates for individuals fighting aggressive cancers. In addition, Dr. Counsell will examine the underwriting and claims adjudication implications.
In this edition of ReCent Medical News, Monique Esterhuizen reflects on how genomics enable us to “look under the hood” of a tumor and develop the most suitable personalized treatment. Furthermore she explores what insurers need to know about these promising cancer treatments.
Neurotechnology is defined as “the application of engineering principles to the understanding, engagement, and repair of the human nervous system.” In this research article, RGA's Hilary Henly, Global Medical Researcher, highlights how the enhanced understanding of how the brain functions and how technology can interact with brain waves is creating new approaches to treat severe or advanced neurological disorders, allowing patients to live longer and healthier lives.
Two years of a worldwide coronavirus pandemic is leaving its imprint on life insurance.
Multiparametric magnetic resonance imaging (mpMRI) is an imaging tool with growing use in diagnosis, risk assessment, and management of individuals with prostate cancer. Explore current challenges with prostate cancer detection and diagnosis, and the role of mpMRI.
In this third interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on advances in cancer therapy.
SCOR's medical experts discuss the lasting impacts of infection
In this second interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on advances in cancer diagnostics.
RGA's Dr. Maryam B. Shapland, Vice President and Medical Director, U.S. Mortality Markets, explores reactive thrombocytosis, a condition associated with higher mortality in acutely ill patients.
In this whitepaper, multiple RGA experts address the status quo of testing for the purposes of early disease detection and look forward to the future of screening.